NCT05877066 2024-04-16
GRASP-DC
Endo Pharmaceuticals
Terminated
Clinical Trials
12 trialsNCT00528606 2017-12-02
CORD-I
Endo Pharmaceuticals
Phase 3 Completed
NCT01444729 2017-10-26
Post Approval Commitment Study
Endo Pharmaceuticals
Completed
NCT00528931 2017-10-05
A Pharmacokinetic Study of AA4500 (XIAFLEXâ„¢, Proposed Name) in Subjects With Dupuytren's Contracture
Endo Pharmaceuticals
Phase 1 Completed
NCT01407068 2017-10-05
Administration of Two Injections for Multiple Dupuytren's Contractures
Endo Pharmaceuticals
Phase 3 Completed
NCT01498640 2017-10-05
Retreatment of Recurrent Dupuytren's Contractures
Endo Pharmaceuticals
Phase 4 Completed
NCT01674634 2017-10-05
Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures
Endo Pharmaceuticals
Phase 3 Completed
NCT02193828 2017-10-05
Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules
Endo Pharmaceuticals
Phase 2 Completed
NCT01588353 2017-03-21
CORD-J
Asahi Kasei Therapeutics Corporation
Phase 3 Completed
NCT00954746 2015-06-16
Longterm Observational Study in Subjects Treated With AA4500 in AUX-CC-854, 856, 857, 858 & 859
Endo Pharmaceuticals
Completed
NCT01715467 2015-06-16
CORRECT
Endo Pharmaceuticals
Completed
NCT01229436 2014-03-17
POINT X
Pfizer
Phase 3 Completed